nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—CYP2D6—Lomustine—hematologic cancer	0.0283	0.056	CbGbCtD
Escitalopram—CYP2D6—Idarubicin—hematologic cancer	0.0252	0.0499	CbGbCtD
Escitalopram—CYP2C19—Bortezomib—hematologic cancer	0.0245	0.0485	CbGbCtD
Escitalopram—CYP2D6—Hydroxyurea—hematologic cancer	0.0214	0.0424	CbGbCtD
Escitalopram—CYP2C19—Thalidomide—hematologic cancer	0.0213	0.0423	CbGbCtD
Escitalopram—CYP2C19—Teniposide—hematologic cancer	0.0204	0.0403	CbGbCtD
Escitalopram—CYP3A4—Bexarotene—hematologic cancer	0.0193	0.0383	CbGbCtD
Escitalopram—CYP2C19—Ifosfamide—hematologic cancer	0.0188	0.0372	CbGbCtD
Escitalopram—CYP2D6—Bortezomib—hematologic cancer	0.0186	0.0369	CbGbCtD
Escitalopram—CYP3A4—Lomustine—hematologic cancer	0.018	0.0356	CbGbCtD
Escitalopram—CYP3A4—Busulfan—hematologic cancer	0.018	0.0356	CbGbCtD
Escitalopram—CYP2C19—Imatinib—hematologic cancer	0.018	0.0356	CbGbCtD
Escitalopram—CYP3A4—Thiotepa—hematologic cancer	0.016	0.0317	CbGbCtD
Escitalopram—CYP2D6—Imatinib—hematologic cancer	0.0136	0.027	CbGbCtD
Escitalopram—CYP3A4—Methoxsalen—hematologic cancer	0.0125	0.0247	CbGbCtD
Escitalopram—CYP2D6—Nilotinib—hematologic cancer	0.0124	0.0246	CbGbCtD
Escitalopram—CYP2D6—Vinorelbine—hematologic cancer	0.0123	0.0244	CbGbCtD
Escitalopram—CYP3A4—Bortezomib—hematologic cancer	0.0118	0.0235	CbGbCtD
Escitalopram—CYP2C19—Prednisone—hematologic cancer	0.0118	0.0234	CbGbCtD
Escitalopram—CYP3A4—Daunorubicin—hematologic cancer	0.0113	0.0224	CbGbCtD
Escitalopram—CYP3A4—Cytarabine—hematologic cancer	0.00999	0.0198	CbGbCtD
Escitalopram—CYP3A4—Teniposide—hematologic cancer	0.00984	0.0195	CbGbCtD
Escitalopram—CYP3A4—Ifosfamide—hematologic cancer	0.00908	0.018	CbGbCtD
Escitalopram—CYP3A4—Imatinib—hematologic cancer	0.00868	0.0172	CbGbCtD
Escitalopram—CYP3A4—Ruxolitinib—hematologic cancer	0.00817	0.0162	CbGbCtD
Escitalopram—CYP3A4—Nilotinib—hematologic cancer	0.00789	0.0156	CbGbCtD
Escitalopram—CYP3A4—Vinorelbine—hematologic cancer	0.00782	0.0155	CbGbCtD
Escitalopram—CYP2D6—Vinblastine—hematologic cancer	0.00758	0.015	CbGbCtD
Escitalopram—CYP2C19—Dexamethasone—hematologic cancer	0.00738	0.0146	CbGbCtD
Escitalopram—CYP3A4—Triamcinolone—hematologic cancer	0.00715	0.0142	CbGbCtD
Escitalopram—CYP3A4—Dasatinib—hematologic cancer	0.00697	0.0138	CbGbCtD
Escitalopram—CYP3A4—Mitoxantrone—hematologic cancer	0.00688	0.0136	CbGbCtD
Escitalopram—CYP3A4—Betamethasone—hematologic cancer	0.00614	0.0122	CbGbCtD
Escitalopram—CYP3A4—Prednisolone—hematologic cancer	0.00605	0.012	CbGbCtD
Escitalopram—CYP3A4—Prednisone—hematologic cancer	0.00572	0.0113	CbGbCtD
Escitalopram—CYP2D6—Dexamethasone—hematologic cancer	0.00561	0.0111	CbGbCtD
Escitalopram—CYP3A4—Irinotecan—hematologic cancer	0.00542	0.0107	CbGbCtD
Escitalopram—CYP3A4—Vinblastine—hematologic cancer	0.00482	0.00954	CbGbCtD
Escitalopram—CYP3A4—Vincristine—hematologic cancer	0.00474	0.00938	CbGbCtD
Escitalopram—CYP2D6—Doxorubicin—hematologic cancer	0.00466	0.00922	CbGbCtD
Escitalopram—CYP3A4—Etoposide—hematologic cancer	0.00434	0.0086	CbGbCtD
Escitalopram—CYP3A4—Dexamethasone—hematologic cancer	0.00357	0.00707	CbGbCtD
Escitalopram—CYP3A4—Doxorubicin—hematologic cancer	0.00296	0.00586	CbGbCtD
Escitalopram—SLC6A3—hematopoietic system—hematologic cancer	0.000435	0.0816	CbGeAlD
Escitalopram—SLC6A4—hematopoietic system—hematologic cancer	0.000398	0.0747	CbGeAlD
Escitalopram—Citalopram—ABCB1—hematologic cancer	0.000368	1	CrCbGaD
Escitalopram—CYP2C19—hematopoietic system—hematologic cancer	0.00033	0.0619	CbGeAlD
Escitalopram—ADRA1A—hematopoietic system—hematologic cancer	0.000326	0.0612	CbGeAlD
Escitalopram—SLC6A2—gonad—hematologic cancer	0.000267	0.05	CbGeAlD
Escitalopram—SLC6A4—blood—hematologic cancer	0.000264	0.0495	CbGeAlD
Escitalopram—SLC6A3—lung—hematologic cancer	0.000252	0.0474	CbGeAlD
Escitalopram—HRH1—hematopoietic system—hematologic cancer	0.000252	0.0474	CbGeAlD
Escitalopram—SLC6A3—testis—hematologic cancer	0.000238	0.0447	CbGeAlD
Escitalopram—SLC6A4—lung—hematologic cancer	0.000231	0.0434	CbGeAlD
Escitalopram—CHRM1—lung—hematologic cancer	0.00023	0.0432	CbGeAlD
Escitalopram—CYP2C19—blood—hematologic cancer	0.000219	0.041	CbGeAlD
Escitalopram—ADRA1A—blood—hematologic cancer	0.000216	0.0405	CbGeAlD
Escitalopram—SLC6A2—lung—hematologic cancer	0.000204	0.0382	CbGeAlD
Escitalopram—CYP3A4—hematopoietic system—hematologic cancer	0.000195	0.0366	CbGeAlD
Escitalopram—SLC6A2—testis—hematologic cancer	0.000192	0.0361	CbGeAlD
Escitalopram—CYP2D6—hematopoietic system—hematologic cancer	0.000192	0.036	CbGeAlD
Escitalopram—HRH1—lung—hematologic cancer	0.000147	0.0275	CbGeAlD
Escitalopram—SLC6A2—lymph node—hematologic cancer	0.000139	0.0261	CbGeAlD
Escitalopram—HRH1—testis—hematologic cancer	0.000138	0.0259	CbGeAlD
Escitalopram—CYP3A4—blood—hematologic cancer	0.000129	0.0243	CbGeAlD
Escitalopram—CYP2D6—blood—hematologic cancer	0.000127	0.0239	CbGeAlD
Escitalopram—CYP2D6—testis—hematologic cancer	0.000105	0.0197	CbGeAlD
Escitalopram—HRH1—lymph node—hematologic cancer	0.0001	0.0188	CbGeAlD
Escitalopram—Flatulence—Epirubicin—hematologic cancer	1.3e-05	3.15e-05	CcSEcCtD
Escitalopram—Tension—Epirubicin—hematologic cancer	1.29e-05	3.13e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.29e-05	3.13e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Betamethasone—hematologic cancer	1.29e-05	3.13e-05	CcSEcCtD
Escitalopram—Dysgeusia—Epirubicin—hematologic cancer	1.29e-05	3.13e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Triamcinolone—hematologic cancer	1.28e-05	3.11e-05	CcSEcCtD
Escitalopram—Nervousness—Epirubicin—hematologic cancer	1.28e-05	3.1e-05	CcSEcCtD
Escitalopram—Back pain—Epirubicin—hematologic cancer	1.27e-05	3.09e-05	CcSEcCtD
Escitalopram—Angiopathy—Doxorubicin—hematologic cancer	1.27e-05	3.08e-05	CcSEcCtD
Escitalopram—Malaise—Methotrexate—hematologic cancer	1.27e-05	3.08e-05	CcSEcCtD
Escitalopram—Dizziness—Etoposide—hematologic cancer	1.27e-05	3.07e-05	CcSEcCtD
Escitalopram—Muscle spasms—Epirubicin—hematologic cancer	1.27e-05	3.07e-05	CcSEcCtD
Escitalopram—Immune system disorder—Doxorubicin—hematologic cancer	1.26e-05	3.07e-05	CcSEcCtD
Escitalopram—Vertigo—Methotrexate—hematologic cancer	1.26e-05	3.07e-05	CcSEcCtD
Escitalopram—Mediastinal disorder—Doxorubicin—hematologic cancer	1.26e-05	3.06e-05	CcSEcCtD
Escitalopram—Leukopenia—Methotrexate—hematologic cancer	1.26e-05	3.05e-05	CcSEcCtD
Escitalopram—Chills—Doxorubicin—hematologic cancer	1.26e-05	3.04e-05	CcSEcCtD
Escitalopram—Urticaria—Dexamethasone—hematologic cancer	1.25e-05	3.04e-05	CcSEcCtD
Escitalopram—Urticaria—Betamethasone—hematologic cancer	1.25e-05	3.04e-05	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.25e-05	3.04e-05	CcSEcCtD
Escitalopram—Dizziness—Prednisolone—hematologic cancer	1.25e-05	3.03e-05	CcSEcCtD
Escitalopram—Arrhythmia—Doxorubicin—hematologic cancer	1.25e-05	3.03e-05	CcSEcCtD
Escitalopram—Asthenia—Triamcinolone—hematologic cancer	1.25e-05	3.03e-05	CcSEcCtD
Escitalopram—Body temperature increased—Betamethasone—hematologic cancer	1.25e-05	3.02e-05	CcSEcCtD
Escitalopram—Abdominal pain—Betamethasone—hematologic cancer	1.25e-05	3.02e-05	CcSEcCtD
Escitalopram—Abdominal pain—Dexamethasone—hematologic cancer	1.25e-05	3.02e-05	CcSEcCtD
Escitalopram—Body temperature increased—Dexamethasone—hematologic cancer	1.25e-05	3.02e-05	CcSEcCtD
Escitalopram—Nausea—Cisplatin—hematologic cancer	1.24e-05	3.01e-05	CcSEcCtD
Escitalopram—Insomnia—Prednisone—hematologic cancer	1.24e-05	3.01e-05	CcSEcCtD
Escitalopram—Vision blurred—Epirubicin—hematologic cancer	1.24e-05	3.01e-05	CcSEcCtD
Escitalopram—Alopecia—Doxorubicin—hematologic cancer	1.24e-05	3e-05	CcSEcCtD
Escitalopram—Paraesthesia—Prednisone—hematologic cancer	1.23e-05	2.99e-05	CcSEcCtD
Escitalopram—Pruritus—Triamcinolone—hematologic cancer	1.23e-05	2.98e-05	CcSEcCtD
Escitalopram—Cough—Methotrexate—hematologic cancer	1.23e-05	2.98e-05	CcSEcCtD
Escitalopram—Mental disorder—Doxorubicin—hematologic cancer	1.23e-05	2.97e-05	CcSEcCtD
Escitalopram—Ill-defined disorder—Epirubicin—hematologic cancer	1.22e-05	2.96e-05	CcSEcCtD
Escitalopram—Convulsion—Methotrexate—hematologic cancer	1.22e-05	2.96e-05	CcSEcCtD
Escitalopram—Vomiting—Etoposide—hematologic cancer	1.22e-05	2.96e-05	CcSEcCtD
Escitalopram—Erythema—Doxorubicin—hematologic cancer	1.22e-05	2.95e-05	CcSEcCtD
Escitalopram—Malnutrition—Doxorubicin—hematologic cancer	1.22e-05	2.95e-05	CcSEcCtD
Escitalopram—Anaemia—Epirubicin—hematologic cancer	1.22e-05	2.95e-05	CcSEcCtD
Escitalopram—Agitation—Epirubicin—hematologic cancer	1.21e-05	2.93e-05	CcSEcCtD
Escitalopram—Dyspepsia—Prednisone—hematologic cancer	1.21e-05	2.93e-05	CcSEcCtD
Escitalopram—Rash—Etoposide—hematologic cancer	1.21e-05	2.93e-05	CcSEcCtD
Escitalopram—Dermatitis—Etoposide—hematologic cancer	1.21e-05	2.93e-05	CcSEcCtD
Escitalopram—Headache—Etoposide—hematologic cancer	1.2e-05	2.91e-05	CcSEcCtD
Escitalopram—Flatulence—Doxorubicin—hematologic cancer	1.2e-05	2.91e-05	CcSEcCtD
Escitalopram—Chest pain—Methotrexate—hematologic cancer	1.2e-05	2.9e-05	CcSEcCtD
Escitalopram—Arthralgia—Methotrexate—hematologic cancer	1.2e-05	2.9e-05	CcSEcCtD
Escitalopram—Myalgia—Methotrexate—hematologic cancer	1.2e-05	2.9e-05	CcSEcCtD
Escitalopram—Tension—Doxorubicin—hematologic cancer	1.2e-05	2.9e-05	CcSEcCtD
Escitalopram—Decreased appetite—Prednisone—hematologic cancer	1.19e-05	2.9e-05	CcSEcCtD
Escitalopram—Dysgeusia—Doxorubicin—hematologic cancer	1.19e-05	2.89e-05	CcSEcCtD
Escitalopram—Rash—Prednisolone—hematologic cancer	1.19e-05	2.89e-05	CcSEcCtD
Escitalopram—Dermatitis—Prednisolone—hematologic cancer	1.19e-05	2.89e-05	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.19e-05	2.88e-05	CcSEcCtD
Escitalopram—Malaise—Epirubicin—hematologic cancer	1.19e-05	2.88e-05	CcSEcCtD
Escitalopram—Fatigue—Prednisone—hematologic cancer	1.18e-05	2.87e-05	CcSEcCtD
Escitalopram—Headache—Prednisolone—hematologic cancer	1.18e-05	2.87e-05	CcSEcCtD
Escitalopram—Discomfort—Methotrexate—hematologic cancer	1.18e-05	2.87e-05	CcSEcCtD
Escitalopram—Nervousness—Doxorubicin—hematologic cancer	1.18e-05	2.87e-05	CcSEcCtD
Escitalopram—Vertigo—Epirubicin—hematologic cancer	1.18e-05	2.87e-05	CcSEcCtD
Escitalopram—Syncope—Epirubicin—hematologic cancer	1.18e-05	2.86e-05	CcSEcCtD
Escitalopram—Leukopenia—Epirubicin—hematologic cancer	1.18e-05	2.86e-05	CcSEcCtD
Escitalopram—Back pain—Doxorubicin—hematologic cancer	1.18e-05	2.86e-05	CcSEcCtD
Escitalopram—Constipation—Prednisone—hematologic cancer	1.17e-05	2.85e-05	CcSEcCtD
Escitalopram—Muscle spasms—Doxorubicin—hematologic cancer	1.17e-05	2.84e-05	CcSEcCtD
Escitalopram—Palpitations—Epirubicin—hematologic cancer	1.16e-05	2.82e-05	CcSEcCtD
Escitalopram—Confusional state—Methotrexate—hematologic cancer	1.16e-05	2.81e-05	CcSEcCtD
Escitalopram—Loss of consciousness—Epirubicin—hematologic cancer	1.16e-05	2.81e-05	CcSEcCtD
Escitalopram—Dizziness—Triamcinolone—hematologic cancer	1.15e-05	2.79e-05	CcSEcCtD
Escitalopram—Cough—Epirubicin—hematologic cancer	1.15e-05	2.79e-05	CcSEcCtD
Escitalopram—Anaphylactic shock—Methotrexate—hematologic cancer	1.15e-05	2.78e-05	CcSEcCtD
Escitalopram—Vision blurred—Doxorubicin—hematologic cancer	1.15e-05	2.78e-05	CcSEcCtD
Escitalopram—Convulsion—Epirubicin—hematologic cancer	1.14e-05	2.77e-05	CcSEcCtD
Escitalopram—Infection—Methotrexate—hematologic cancer	1.14e-05	2.77e-05	CcSEcCtD
Escitalopram—Nausea—Etoposide—hematologic cancer	1.14e-05	2.76e-05	CcSEcCtD
Escitalopram—Hypertension—Epirubicin—hematologic cancer	1.14e-05	2.76e-05	CcSEcCtD
Escitalopram—Feeling abnormal—Prednisone—hematologic cancer	1.13e-05	2.75e-05	CcSEcCtD
Escitalopram—Asthenia—Betamethasone—hematologic cancer	1.13e-05	2.74e-05	CcSEcCtD
Escitalopram—Asthenia—Dexamethasone—hematologic cancer	1.13e-05	2.74e-05	CcSEcCtD
Escitalopram—Ill-defined disorder—Doxorubicin—hematologic cancer	1.13e-05	2.74e-05	CcSEcCtD
Escitalopram—Nervous system disorder—Methotrexate—hematologic cancer	1.13e-05	2.73e-05	CcSEcCtD
Escitalopram—Anaemia—Doxorubicin—hematologic cancer	1.13e-05	2.73e-05	CcSEcCtD
Escitalopram—Thrombocytopenia—Methotrexate—hematologic cancer	1.12e-05	2.73e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Prednisone—hematologic cancer	1.12e-05	2.72e-05	CcSEcCtD
Escitalopram—Nausea—Prednisolone—hematologic cancer	1.12e-05	2.72e-05	CcSEcCtD
Escitalopram—Arthralgia—Epirubicin—hematologic cancer	1.12e-05	2.72e-05	CcSEcCtD
Escitalopram—Chest pain—Epirubicin—hematologic cancer	1.12e-05	2.72e-05	CcSEcCtD
Escitalopram—Myalgia—Epirubicin—hematologic cancer	1.12e-05	2.72e-05	CcSEcCtD
Escitalopram—Agitation—Doxorubicin—hematologic cancer	1.12e-05	2.71e-05	CcSEcCtD
Escitalopram—Anxiety—Epirubicin—hematologic cancer	1.12e-05	2.71e-05	CcSEcCtD
Escitalopram—Pruritus—Dexamethasone—hematologic cancer	1.12e-05	2.71e-05	CcSEcCtD
Escitalopram—Pruritus—Betamethasone—hematologic cancer	1.12e-05	2.71e-05	CcSEcCtD
Escitalopram—Skin disorder—Methotrexate—hematologic cancer	1.12e-05	2.7e-05	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.11e-05	2.7e-05	CcSEcCtD
Escitalopram—Hyperhidrosis—Methotrexate—hematologic cancer	1.11e-05	2.69e-05	CcSEcCtD
Escitalopram—Discomfort—Epirubicin—hematologic cancer	1.11e-05	2.69e-05	CcSEcCtD
Escitalopram—Vomiting—Triamcinolone—hematologic cancer	1.11e-05	2.68e-05	CcSEcCtD
Escitalopram—Malaise—Doxorubicin—hematologic cancer	1.1e-05	2.66e-05	CcSEcCtD
Escitalopram—Rash—Triamcinolone—hematologic cancer	1.1e-05	2.66e-05	CcSEcCtD
Escitalopram—Dry mouth—Epirubicin—hematologic cancer	1.1e-05	2.66e-05	CcSEcCtD
Escitalopram—Dermatitis—Triamcinolone—hematologic cancer	1.1e-05	2.66e-05	CcSEcCtD
Escitalopram—Vertigo—Doxorubicin—hematologic cancer	1.09e-05	2.65e-05	CcSEcCtD
Escitalopram—Anorexia—Methotrexate—hematologic cancer	1.09e-05	2.65e-05	CcSEcCtD
Escitalopram—Syncope—Doxorubicin—hematologic cancer	1.09e-05	2.65e-05	CcSEcCtD
Escitalopram—Urticaria—Prednisone—hematologic cancer	1.09e-05	2.65e-05	CcSEcCtD
Escitalopram—Leukopenia—Doxorubicin—hematologic cancer	1.09e-05	2.64e-05	CcSEcCtD
Escitalopram—Headache—Triamcinolone—hematologic cancer	1.09e-05	2.64e-05	CcSEcCtD
Escitalopram—Body temperature increased—Prednisone—hematologic cancer	1.09e-05	2.63e-05	CcSEcCtD
Escitalopram—Abdominal pain—Prednisone—hematologic cancer	1.09e-05	2.63e-05	CcSEcCtD
Escitalopram—Confusional state—Epirubicin—hematologic cancer	1.08e-05	2.63e-05	CcSEcCtD
Escitalopram—Diarrhoea—Dexamethasone—hematologic cancer	1.08e-05	2.62e-05	CcSEcCtD
Escitalopram—Diarrhoea—Betamethasone—hematologic cancer	1.08e-05	2.62e-05	CcSEcCtD
Escitalopram—Palpitations—Doxorubicin—hematologic cancer	1.08e-05	2.61e-05	CcSEcCtD
Escitalopram—Anaphylactic shock—Epirubicin—hematologic cancer	1.07e-05	2.61e-05	CcSEcCtD
Escitalopram—Oedema—Epirubicin—hematologic cancer	1.07e-05	2.61e-05	CcSEcCtD
Escitalopram—Hypotension—Methotrexate—hematologic cancer	1.07e-05	2.6e-05	CcSEcCtD
Escitalopram—Loss of consciousness—Doxorubicin—hematologic cancer	1.07e-05	2.6e-05	CcSEcCtD
Escitalopram—Infection—Epirubicin—hematologic cancer	1.07e-05	2.59e-05	CcSEcCtD
Escitalopram—Cough—Doxorubicin—hematologic cancer	1.06e-05	2.58e-05	CcSEcCtD
Escitalopram—Shock—Epirubicin—hematologic cancer	1.06e-05	2.56e-05	CcSEcCtD
Escitalopram—Convulsion—Doxorubicin—hematologic cancer	1.06e-05	2.56e-05	CcSEcCtD
Escitalopram—Nervous system disorder—Epirubicin—hematologic cancer	1.05e-05	2.56e-05	CcSEcCtD
Escitalopram—Thrombocytopenia—Epirubicin—hematologic cancer	1.05e-05	2.55e-05	CcSEcCtD
Escitalopram—Hypertension—Doxorubicin—hematologic cancer	1.05e-05	2.55e-05	CcSEcCtD
Escitalopram—Tachycardia—Epirubicin—hematologic cancer	1.05e-05	2.54e-05	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.05e-05	2.54e-05	CcSEcCtD
Escitalopram—Skin disorder—Epirubicin—hematologic cancer	1.04e-05	2.53e-05	CcSEcCtD
Escitalopram—Dizziness—Betamethasone—hematologic cancer	1.04e-05	2.53e-05	CcSEcCtD
Escitalopram—Dizziness—Dexamethasone—hematologic cancer	1.04e-05	2.53e-05	CcSEcCtD
Escitalopram—Hyperhidrosis—Epirubicin—hematologic cancer	1.04e-05	2.52e-05	CcSEcCtD
Escitalopram—Insomnia—Methotrexate—hematologic cancer	1.04e-05	2.52e-05	CcSEcCtD
Escitalopram—Chest pain—Doxorubicin—hematologic cancer	1.04e-05	2.52e-05	CcSEcCtD
Escitalopram—Arthralgia—Doxorubicin—hematologic cancer	1.04e-05	2.52e-05	CcSEcCtD
Escitalopram—Myalgia—Doxorubicin—hematologic cancer	1.04e-05	2.52e-05	CcSEcCtD
Escitalopram—Anxiety—Doxorubicin—hematologic cancer	1.03e-05	2.51e-05	CcSEcCtD
Escitalopram—Nausea—Triamcinolone—hematologic cancer	1.03e-05	2.5e-05	CcSEcCtD
Escitalopram—Paraesthesia—Methotrexate—hematologic cancer	1.03e-05	2.5e-05	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.03e-05	2.5e-05	CcSEcCtD
Escitalopram—Discomfort—Doxorubicin—hematologic cancer	1.02e-05	2.48e-05	CcSEcCtD
Escitalopram—Anorexia—Epirubicin—hematologic cancer	1.02e-05	2.48e-05	CcSEcCtD
Escitalopram—Dyspnoea—Methotrexate—hematologic cancer	1.02e-05	2.48e-05	CcSEcCtD
Escitalopram—Somnolence—Methotrexate—hematologic cancer	1.02e-05	2.48e-05	CcSEcCtD
Escitalopram—Dry mouth—Doxorubicin—hematologic cancer	1.01e-05	2.46e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Prednisone—hematologic cancer	1.01e-05	2.45e-05	CcSEcCtD
Escitalopram—Dyspepsia—Methotrexate—hematologic cancer	1.01e-05	2.45e-05	CcSEcCtD
Escitalopram—Hypotension—Epirubicin—hematologic cancer	1e-05	2.43e-05	CcSEcCtD
Escitalopram—Vomiting—Dexamethasone—hematologic cancer	1e-05	2.43e-05	CcSEcCtD
Escitalopram—Vomiting—Betamethasone—hematologic cancer	1e-05	2.43e-05	CcSEcCtD
Escitalopram—Confusional state—Doxorubicin—hematologic cancer	1e-05	2.43e-05	CcSEcCtD
Escitalopram—Decreased appetite—Methotrexate—hematologic cancer	9.98e-06	2.42e-05	CcSEcCtD
Escitalopram—Rash—Dexamethasone—hematologic cancer	9.95e-06	2.41e-05	CcSEcCtD
Escitalopram—Rash—Betamethasone—hematologic cancer	9.95e-06	2.41e-05	CcSEcCtD
Escitalopram—Anaphylactic shock—Doxorubicin—hematologic cancer	9.94e-06	2.41e-05	CcSEcCtD
Escitalopram—Oedema—Doxorubicin—hematologic cancer	9.94e-06	2.41e-05	CcSEcCtD
Escitalopram—Dermatitis—Betamethasone—hematologic cancer	9.94e-06	2.41e-05	CcSEcCtD
Escitalopram—Dermatitis—Dexamethasone—hematologic cancer	9.94e-06	2.41e-05	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Methotrexate—hematologic cancer	9.91e-06	2.4e-05	CcSEcCtD
Escitalopram—Fatigue—Methotrexate—hematologic cancer	9.9e-06	2.4e-05	CcSEcCtD
Escitalopram—Headache—Dexamethasone—hematologic cancer	9.88e-06	2.4e-05	CcSEcCtD
Escitalopram—Headache—Betamethasone—hematologic cancer	9.88e-06	2.4e-05	CcSEcCtD
Escitalopram—Infection—Doxorubicin—hematologic cancer	9.88e-06	2.4e-05	CcSEcCtD
Escitalopram—Asthenia—Prednisone—hematologic cancer	9.86e-06	2.39e-05	CcSEcCtD
Escitalopram—Pain—Methotrexate—hematologic cancer	9.82e-06	2.38e-05	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Epirubicin—hematologic cancer	9.79e-06	2.37e-05	CcSEcCtD
Escitalopram—Shock—Doxorubicin—hematologic cancer	9.78e-06	2.37e-05	CcSEcCtD
Escitalopram—Nervous system disorder—Doxorubicin—hematologic cancer	9.75e-06	2.36e-05	CcSEcCtD
Escitalopram—Thrombocytopenia—Doxorubicin—hematologic cancer	9.73e-06	2.36e-05	CcSEcCtD
Escitalopram—Pruritus—Prednisone—hematologic cancer	9.72e-06	2.36e-05	CcSEcCtD
Escitalopram—Insomnia—Epirubicin—hematologic cancer	9.72e-06	2.36e-05	CcSEcCtD
Escitalopram—Tachycardia—Doxorubicin—hematologic cancer	9.7e-06	2.35e-05	CcSEcCtD
Escitalopram—Skin disorder—Doxorubicin—hematologic cancer	9.66e-06	2.34e-05	CcSEcCtD
Escitalopram—Paraesthesia—Epirubicin—hematologic cancer	9.65e-06	2.34e-05	CcSEcCtD
Escitalopram—Hyperhidrosis—Doxorubicin—hematologic cancer	9.61e-06	2.33e-05	CcSEcCtD
Escitalopram—Dyspnoea—Epirubicin—hematologic cancer	9.58e-06	2.32e-05	CcSEcCtD
Escitalopram—Somnolence—Epirubicin—hematologic cancer	9.55e-06	2.32e-05	CcSEcCtD
Escitalopram—Anorexia—Doxorubicin—hematologic cancer	9.48e-06	2.3e-05	CcSEcCtD
Escitalopram—Feeling abnormal—Methotrexate—hematologic cancer	9.46e-06	2.29e-05	CcSEcCtD
Escitalopram—Dyspepsia—Epirubicin—hematologic cancer	9.46e-06	2.29e-05	CcSEcCtD
Escitalopram—Diarrhoea—Prednisone—hematologic cancer	9.4e-06	2.28e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Methotrexate—hematologic cancer	9.39e-06	2.28e-05	CcSEcCtD
Escitalopram—Nausea—Betamethasone—hematologic cancer	9.37e-06	2.27e-05	CcSEcCtD
Escitalopram—Nausea—Dexamethasone—hematologic cancer	9.37e-06	2.27e-05	CcSEcCtD
Escitalopram—Decreased appetite—Epirubicin—hematologic cancer	9.34e-06	2.27e-05	CcSEcCtD
Escitalopram—Hypotension—Doxorubicin—hematologic cancer	9.29e-06	2.25e-05	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Epirubicin—hematologic cancer	9.28e-06	2.25e-05	CcSEcCtD
Escitalopram—Fatigue—Epirubicin—hematologic cancer	9.26e-06	2.25e-05	CcSEcCtD
Escitalopram—Pain—Epirubicin—hematologic cancer	9.19e-06	2.23e-05	CcSEcCtD
Escitalopram—Constipation—Epirubicin—hematologic cancer	9.19e-06	2.23e-05	CcSEcCtD
Escitalopram—Urticaria—Methotrexate—hematologic cancer	9.12e-06	2.21e-05	CcSEcCtD
Escitalopram—Dizziness—Prednisone—hematologic cancer	9.08e-06	2.2e-05	CcSEcCtD
Escitalopram—Body temperature increased—Methotrexate—hematologic cancer	9.08e-06	2.2e-05	CcSEcCtD
Escitalopram—Abdominal pain—Methotrexate—hematologic cancer	9.08e-06	2.2e-05	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	9.06e-06	2.2e-05	CcSEcCtD
Escitalopram—Insomnia—Doxorubicin—hematologic cancer	8.99e-06	2.18e-05	CcSEcCtD
Escitalopram—Paraesthesia—Doxorubicin—hematologic cancer	8.93e-06	2.16e-05	CcSEcCtD
Escitalopram—Dyspnoea—Doxorubicin—hematologic cancer	8.86e-06	2.15e-05	CcSEcCtD
Escitalopram—Feeling abnormal—Epirubicin—hematologic cancer	8.85e-06	2.15e-05	CcSEcCtD
Escitalopram—Somnolence—Doxorubicin—hematologic cancer	8.84e-06	2.14e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Epirubicin—hematologic cancer	8.79e-06	2.13e-05	CcSEcCtD
Escitalopram—Dyspepsia—Doxorubicin—hematologic cancer	8.75e-06	2.12e-05	CcSEcCtD
Escitalopram—Vomiting—Prednisone—hematologic cancer	8.73e-06	2.12e-05	CcSEcCtD
Escitalopram—Rash—Prednisone—hematologic cancer	8.66e-06	2.1e-05	CcSEcCtD
Escitalopram—Dermatitis—Prednisone—hematologic cancer	8.65e-06	2.1e-05	CcSEcCtD
Escitalopram—Decreased appetite—Doxorubicin—hematologic cancer	8.64e-06	2.1e-05	CcSEcCtD
Escitalopram—Headache—Prednisone—hematologic cancer	8.61e-06	2.09e-05	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Doxorubicin—hematologic cancer	8.58e-06	2.08e-05	CcSEcCtD
Escitalopram—Fatigue—Doxorubicin—hematologic cancer	8.57e-06	2.08e-05	CcSEcCtD
Escitalopram—Urticaria—Epirubicin—hematologic cancer	8.53e-06	2.07e-05	CcSEcCtD
Escitalopram—Pain—Doxorubicin—hematologic cancer	8.5e-06	2.06e-05	CcSEcCtD
Escitalopram—Constipation—Doxorubicin—hematologic cancer	8.5e-06	2.06e-05	CcSEcCtD
Escitalopram—Abdominal pain—Epirubicin—hematologic cancer	8.49e-06	2.06e-05	CcSEcCtD
Escitalopram—Body temperature increased—Epirubicin—hematologic cancer	8.49e-06	2.06e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Methotrexate—hematologic cancer	8.46e-06	2.05e-05	CcSEcCtD
Escitalopram—Asthenia—Methotrexate—hematologic cancer	8.24e-06	2e-05	CcSEcCtD
Escitalopram—Feeling abnormal—Doxorubicin—hematologic cancer	8.19e-06	1.99e-05	CcSEcCtD
Escitalopram—Nausea—Prednisone—hematologic cancer	8.16e-06	1.98e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Doxorubicin—hematologic cancer	8.13e-06	1.97e-05	CcSEcCtD
Escitalopram—Pruritus—Methotrexate—hematologic cancer	8.12e-06	1.97e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Epirubicin—hematologic cancer	7.92e-06	1.92e-05	CcSEcCtD
Escitalopram—Urticaria—Doxorubicin—hematologic cancer	7.9e-06	1.92e-05	CcSEcCtD
Escitalopram—Abdominal pain—Doxorubicin—hematologic cancer	7.86e-06	1.91e-05	CcSEcCtD
Escitalopram—Body temperature increased—Doxorubicin—hematologic cancer	7.86e-06	1.91e-05	CcSEcCtD
Escitalopram—Diarrhoea—Methotrexate—hematologic cancer	7.85e-06	1.91e-05	CcSEcCtD
Escitalopram—Asthenia—Epirubicin—hematologic cancer	7.71e-06	1.87e-05	CcSEcCtD
Escitalopram—Pruritus—Epirubicin—hematologic cancer	7.6e-06	1.84e-05	CcSEcCtD
Escitalopram—Dizziness—Methotrexate—hematologic cancer	7.59e-06	1.84e-05	CcSEcCtD
Escitalopram—Diarrhoea—Epirubicin—hematologic cancer	7.35e-06	1.78e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Doxorubicin—hematologic cancer	7.32e-06	1.78e-05	CcSEcCtD
Escitalopram—Vomiting—Methotrexate—hematologic cancer	7.3e-06	1.77e-05	CcSEcCtD
Escitalopram—Rash—Methotrexate—hematologic cancer	7.24e-06	1.76e-05	CcSEcCtD
Escitalopram—Dermatitis—Methotrexate—hematologic cancer	7.23e-06	1.75e-05	CcSEcCtD
Escitalopram—Headache—Methotrexate—hematologic cancer	7.19e-06	1.74e-05	CcSEcCtD
Escitalopram—Asthenia—Doxorubicin—hematologic cancer	7.13e-06	1.73e-05	CcSEcCtD
Escitalopram—Dizziness—Epirubicin—hematologic cancer	7.1e-06	1.72e-05	CcSEcCtD
Escitalopram—Pruritus—Doxorubicin—hematologic cancer	7.03e-06	1.71e-05	CcSEcCtD
Escitalopram—Vomiting—Epirubicin—hematologic cancer	6.83e-06	1.66e-05	CcSEcCtD
Escitalopram—Nausea—Methotrexate—hematologic cancer	6.82e-06	1.65e-05	CcSEcCtD
Escitalopram—Diarrhoea—Doxorubicin—hematologic cancer	6.8e-06	1.65e-05	CcSEcCtD
Escitalopram—Rash—Epirubicin—hematologic cancer	6.77e-06	1.64e-05	CcSEcCtD
Escitalopram—Dermatitis—Epirubicin—hematologic cancer	6.77e-06	1.64e-05	CcSEcCtD
Escitalopram—Headache—Epirubicin—hematologic cancer	6.73e-06	1.63e-05	CcSEcCtD
Escitalopram—Dizziness—Doxorubicin—hematologic cancer	6.57e-06	1.59e-05	CcSEcCtD
Escitalopram—Nausea—Epirubicin—hematologic cancer	6.38e-06	1.55e-05	CcSEcCtD
Escitalopram—Vomiting—Doxorubicin—hematologic cancer	6.32e-06	1.53e-05	CcSEcCtD
Escitalopram—Rash—Doxorubicin—hematologic cancer	6.27e-06	1.52e-05	CcSEcCtD
Escitalopram—Dermatitis—Doxorubicin—hematologic cancer	6.26e-06	1.52e-05	CcSEcCtD
Escitalopram—Headache—Doxorubicin—hematologic cancer	6.23e-06	1.51e-05	CcSEcCtD
Escitalopram—Nausea—Doxorubicin—hematologic cancer	5.9e-06	1.43e-05	CcSEcCtD
Escitalopram—HRH1—Signaling Pathways—ESR1—hematologic cancer	5.03e-06	6.52e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ESR1—hematologic cancer	5.01e-06	6.5e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NUP214—hematologic cancer	5.01e-06	6.5e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—FN1—hematologic cancer	4.96e-06	6.45e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—FN1—hematologic cancer	4.95e-06	6.42e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTP1—hematologic cancer	4.95e-06	6.42e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GSTM1—hematologic cancer	4.94e-06	6.42e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—NCOR1—hematologic cancer	4.94e-06	6.42e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ESR1—hematologic cancer	4.93e-06	6.4e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—MTR—hematologic cancer	4.91e-06	6.37e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ABCG2—hematologic cancer	4.91e-06	6.37e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—BAD—hematologic cancer	4.91e-06	6.37e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NFKBIA—hematologic cancer	4.91e-06	6.37e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—BAD—hematologic cancer	4.89e-06	6.35e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NFKBIA—hematologic cancer	4.89e-06	6.35e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—FN1—hematologic cancer	4.87e-06	6.32e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NOTCH1—hematologic cancer	4.86e-06	6.31e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MAP2K1—hematologic cancer	4.85e-06	6.3e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	4.84e-06	6.29e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CD—hematologic cancer	4.82e-06	6.26e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—BAD—hematologic cancer	4.81e-06	6.25e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NFKBIA—hematologic cancer	4.81e-06	6.25e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ENO2—hematologic cancer	4.81e-06	6.25e-05	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—PIK3CA—hematologic cancer	4.77e-06	6.2e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NOTCH1—hematologic cancer	4.77e-06	6.19e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CD80—hematologic cancer	4.76e-06	6.18e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CG—hematologic cancer	4.75e-06	6.17e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KIT—hematologic cancer	4.75e-06	6.17e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—NRAS—hematologic cancer	4.75e-06	6.17e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CD80—hematologic cancer	4.74e-06	6.16e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	4.74e-06	6.15e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KIT—hematologic cancer	4.74e-06	6.15e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	4.74e-06	6.15e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—KRAS—hematologic cancer	4.72e-06	6.13e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ABCB1—hematologic cancer	4.68e-06	6.08e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CD80—hematologic cancer	4.67e-06	6.06e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PTPN11—hematologic cancer	4.67e-06	6.06e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTT1—hematologic cancer	4.67e-06	6.06e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KIT—hematologic cancer	4.66e-06	6.05e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CG—hematologic cancer	4.66e-06	6.05e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—NRAS—hematologic cancer	4.66e-06	6.05e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	4.65e-06	6.04e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—FGF2—hematologic cancer	4.61e-06	5.99e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PTPN11—hematologic cancer	4.58e-06	5.95e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SDC1—hematologic cancer	4.56e-06	5.92e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3R1—hematologic cancer	4.55e-06	5.91e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—MAPK3—hematologic cancer	4.55e-06	5.91e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—NCOR1—hematologic cancer	4.55e-06	5.9e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTM1—hematologic cancer	4.55e-06	5.9e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	4.54e-06	5.89e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CREB1—hematologic cancer	4.52e-06	5.87e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CREB1—hematologic cancer	4.51e-06	5.85e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—BRAF—hematologic cancer	4.47e-06	5.8e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—MAPK3—hematologic cancer	4.46e-06	5.8e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—BRAF—hematologic cancer	4.45e-06	5.78e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CREB1—hematologic cancer	4.44e-06	5.76e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CCL2—hematologic cancer	4.42e-06	5.74e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—JAK2—hematologic cancer	4.42e-06	5.74e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL6R—hematologic cancer	4.41e-06	5.73e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CCL2—hematologic cancer	4.41e-06	5.73e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CREBBP—hematologic cancer	4.4e-06	5.72e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL6R—hematologic cancer	4.4e-06	5.71e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	4.39e-06	5.7e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	4.38e-06	5.69e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—MTHFR—hematologic cancer	4.37e-06	5.67e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	4.34e-06	5.64e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PIK3CA—hematologic cancer	4.34e-06	5.63e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	4.33e-06	5.62e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	4.32e-06	5.61e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MDM2—hematologic cancer	4.32e-06	5.61e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MAP2K1—hematologic cancer	4.2e-06	5.46e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MTOR—hematologic cancer	4.2e-06	5.45e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CB—hematologic cancer	4.2e-06	5.45e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	4.19e-06	5.44e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CD—hematologic cancer	4.18e-06	5.42e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	4.16e-06	5.4e-05	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—PIK3CA—hematologic cancer	4.14e-06	5.37e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	4.13e-06	5.36e-05	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	4.12e-06	5.35e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	4.1e-06	5.32e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—KRAS—hematologic cancer	4.09e-06	5.31e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	4.08e-06	5.29e-05	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	4.06e-06	5.27e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—MTHFR—hematologic cancer	4.02e-06	5.22e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	4.01e-06	5.21e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—HRAS—hematologic cancer	4.01e-06	5.21e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—FGF2—hematologic cancer	4e-06	5.19e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—FGF2—hematologic cancer	3.99e-06	5.17e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3R1—hematologic cancer	3.94e-06	5.12e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CDKN1B—hematologic cancer	3.94e-06	5.12e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	3.93e-06	5.1e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	3.92e-06	5.09e-05	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—AKT1—hematologic cancer	3.9e-06	5.06e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NQO1—hematologic cancer	3.88e-06	5.03e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CD44—hematologic cancer	3.88e-06	5.03e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	3.87e-06	5.02e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CASP3—hematologic cancer	3.86e-06	5.02e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IL2—hematologic cancer	3.86e-06	5.01e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.85e-06	5e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—IL6—hematologic cancer	3.84e-06	4.98e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—JAK2—hematologic cancer	3.83e-06	4.98e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—JAK2—hematologic cancer	3.82e-06	4.96e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	3.76e-06	4.88e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CCND1—hematologic cancer	3.76e-06	4.88e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PIK3CA—hematologic cancer	3.76e-06	4.88e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—JUN—hematologic cancer	3.75e-06	4.87e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	3.74e-06	4.86e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MDM2—hematologic cancer	3.74e-06	4.86e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MDM2—hematologic cancer	3.73e-06	4.84e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	3.69e-06	4.79e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	3.67e-06	4.77e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CG—hematologic cancer	3.67e-06	4.76e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYCS—hematologic cancer	3.67e-06	4.76e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.65e-06	4.73e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MTOR—hematologic cancer	3.64e-06	4.73e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CB—hematologic cancer	3.64e-06	4.73e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CDKN1A—hematologic cancer	3.64e-06	4.72e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PTEN—hematologic cancer	3.63e-06	4.71e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MTOR—hematologic cancer	3.63e-06	4.71e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	3.63e-06	4.71e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	3.57e-06	4.64e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	3.57e-06	4.64e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MAPK8—hematologic cancer	3.55e-06	4.61e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—AKT1—hematologic cancer	3.54e-06	4.6e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—HRAS—hematologic cancer	3.48e-06	4.51e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	3.46e-06	4.5e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EP300—hematologic cancer	3.46e-06	4.49e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CDKN1B—hematologic cancer	3.42e-06	4.44e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	3.41e-06	4.43e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	3.41e-06	4.42e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CREBBP—hematologic cancer	3.4e-06	4.42e-05	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—AKT1—hematologic cancer	3.38e-06	4.39e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CG—hematologic cancer	3.38e-06	4.38e-05	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	3.37e-06	4.37e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—SRC—hematologic cancer	3.37e-06	4.37e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	3.35e-06	4.35e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CASP3—hematologic cancer	3.35e-06	4.35e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL2—hematologic cancer	3.34e-06	4.34e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CASP3—hematologic cancer	3.34e-06	4.33e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL2—hematologic cancer	3.33e-06	4.33e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—IL6—hematologic cancer	3.33e-06	4.32e-05	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	3.32e-06	4.31e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—IL6—hematologic cancer	3.32e-06	4.3e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	3.29e-06	4.27e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL2—hematologic cancer	3.28e-06	4.26e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	3.28e-06	4.26e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	3.26e-06	4.24e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CCND1—hematologic cancer	3.26e-06	4.23e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—JUN—hematologic cancer	3.25e-06	4.22e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CCND1—hematologic cancer	3.25e-06	4.22e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—STAT3—hematologic cancer	3.25e-06	4.22e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—JUN—hematologic cancer	3.24e-06	4.21e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NRAS—hematologic cancer	3.24e-06	4.2e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.23e-06	4.2e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CD—hematologic cancer	3.23e-06	4.19e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	3.2e-06	4.15e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—JUN—hematologic cancer	3.19e-06	4.14e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ALB—hematologic cancer	3.18e-06	4.13e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CDKN1A—hematologic cancer	3.15e-06	4.09e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PTEN—hematologic cancer	3.15e-06	4.08e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	3.14e-06	4.08e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PTEN—hematologic cancer	3.14e-06	4.07e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CREBBP—hematologic cancer	3.13e-06	4.06e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	3.1e-06	4.03e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	3.09e-06	4.02e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	3.09e-06	4.01e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MAPK8—hematologic cancer	3.08e-06	4e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—AKT1—hematologic cancer	3.07e-06	3.98e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	3.07e-06	3.98e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.06e-06	3.97e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	3.06e-06	3.97e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3R1—hematologic cancer	3.05e-06	3.96e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	3.02e-06	3.92e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MYC—hematologic cancer	3.02e-06	3.92e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	3.01e-06	3.91e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	3.01e-06	3.91e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EP300—hematologic cancer	3e-06	3.89e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EP300—hematologic cancer	2.99e-06	3.88e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.97e-06	3.86e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.97e-06	3.86e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.97e-06	3.85e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EP300—hematologic cancer	2.94e-06	3.82e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ALB—hematologic cancer	2.93e-06	3.8e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SRC—hematologic cancer	2.92e-06	3.79e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SRC—hematologic cancer	2.91e-06	3.78e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SRC—hematologic cancer	2.86e-06	3.72e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—VEGFA—hematologic cancer	2.84e-06	3.69e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	2.83e-06	3.68e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—STAT3—hematologic cancer	2.81e-06	3.65e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CB—hematologic cancer	2.81e-06	3.65e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NRAS—hematologic cancer	2.81e-06	3.64e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—STAT3—hematologic cancer	2.8e-06	3.64e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.8e-06	3.64e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NRAS—hematologic cancer	2.8e-06	3.63e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	2.79e-06	3.62e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—KRAS—hematologic cancer	2.79e-06	3.62e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	2.76e-06	3.58e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	2.75e-06	3.58e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MAPK3—hematologic cancer	2.69e-06	3.49e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	2.68e-06	3.48e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	2.64e-06	3.42e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.63e-06	3.41e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MYC—hematologic cancer	2.61e-06	3.39e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TGFB1—hematologic cancer	2.61e-06	3.39e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MYC—hematologic cancer	2.61e-06	3.38e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	2.6e-06	3.37e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.59e-06	3.36e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MYC—hematologic cancer	2.57e-06	3.33e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	2.56e-06	3.32e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	2.56e-06	3.32e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TP53—hematologic cancer	2.48e-06	3.22e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTEN—hematologic cancer	2.43e-06	3.15e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KRAS—hematologic cancer	2.42e-06	3.14e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KRAS—hematologic cancer	2.41e-06	3.13e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	2.37e-06	3.08e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HRAS—hematologic cancer	2.37e-06	3.08e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—EP300—hematologic cancer	2.32e-06	3.01e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IL6—hematologic cancer	2.27e-06	2.94e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTEN—hematologic cancer	2.23e-06	2.9e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	2.22e-06	2.88e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	2.21e-06	2.87e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.21e-06	2.87e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	2.18e-06	2.83e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TP53—hematologic cancer	2.15e-06	2.79e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TP53—hematologic cancer	2.14e-06	2.78e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—EP300—hematologic cancer	2.13e-06	2.77e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TP53—hematologic cancer	2.11e-06	2.73e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—AKT1—hematologic cancer	2.09e-06	2.72e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HRAS—hematologic cancer	2.05e-06	2.67e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HRAS—hematologic cancer	2.05e-06	2.66e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.05e-06	2.66e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	2.01e-06	2.62e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL6—hematologic cancer	1.96e-06	2.55e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL6—hematologic cancer	1.96e-06	2.54e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.94e-06	2.52e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL6—hematologic cancer	1.93e-06	2.5e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ALB—hematologic cancer	1.92e-06	2.49e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.83e-06	2.38e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AKT1—hematologic cancer	1.81e-06	2.35e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AKT1—hematologic cancer	1.81e-06	2.35e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	1.78e-06	2.31e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.71e-06	2.23e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.69e-06	2.2e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.58e-06	2.05e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTEN—hematologic cancer	1.46e-06	1.9e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—AKT1—hematologic cancer	1.4e-06	1.82e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—EP300—hematologic cancer	1.39e-06	1.81e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—AKT1—hematologic cancer	1.29e-06	1.67e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.03e-06	1.34e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—AKT1—hematologic cancer	8.42e-07	1.09e-05	CbGpPWpGaD
